

Original Article

The up-regulation of miR-300 in gastric cancer and its effects on cells malignancy

Zhen Shen, Chunsheng Li, Kai Zhang, Wei Yu, Huijie Xiao, Bo Li, Tongjun Liu

Department of Colorectal & Anal Surgery China-Japan Union Hospital of Jilin University, China

Received March 3, 2015; Accepted May 12, 2015; Epub May 15, 2015; Published May 30, 2015

Abstract: Objective: In this study, we investigated the role of miR-300 in regulating cell proliferation and invasion of gastric cancer cells. Methods: MicroRNA and protein expression patterns were compared between gastric cancer tissue and normal tissue and between two different prognostic groups. The up-regulation of miR-300 was confirmed by real-time reverse transcription polymerase chain reaction and its expression was analyzed in AGS gastric cancer cells. Results: We observed that miR-300 expression was frequently and dramatically up-regulated in human gastric cancer tissues and cell lines compared with the matched adjacent normal tissues and cells. We further showed that transient and stable over-expression of miR-300 could promote cell proliferation and cell cycle progression. Moreover, p53, a key inhibitor of cell cycle, was verified as a direct target of miR-300, suggesting that miR-300 might promote gastric cancer cell proliferation and invasion by increasing p53 expression. Conclusion: Our findings indicated that miR-300 up-regulation might exert some sort of antagonistic function by targeting p53 in gastric cancer cell proliferation during gastric tumorigenesis.

Keywords: miR-300, p53, gastric cancer, AGS, target therapy

Introduction

As the third leading culprit in cancer incidence worldwide [1], gastric cancer (GC) continues to pose significant diagnostic, prognostic and therapeutic tribulations for clinicians. The American Joint Committee on Cancer (AJCC) TNM staging system is currently the only prognostic classification used in clinical practice to select patients for adjuvant chemotherapy [2-4]. However, the AJCC stage fails to predict recurrence accurately in many patients undergoing curative surgery for localized GC. This highlights the need for new biomarkers for a more precise prediction of high-risk patients with GC recurrence and consequently improved personalized cancer care.

miRNAs are a novel class of small noncoding RNAs that typically inhibit the translation and stability of messenger RNAs (mRNAs) by binding to the 3'-untranslated regions (3'-UTR) of their target mRNAs [5]. miRNAs have [6-8] nucleotides and are found in all multi-cellular eukaryotic cells. miRNAs have important roles

in various biological and pathological processes, such as development, cell proliferation, differentiation, apoptosis, inflammation, stress response and migration [7-9]. Increasing evidences have suggested that miRNAs are deregulated or upregulated in all types of cancers, acting either as tumor suppressors (e.g. miR-34, miR-15/16, let-7, miR 200 family) or as oncogenes (e.g. miR-155, miR-222/221, miR-17-5p, miR-21) [1, 3, 8, 10], in which the miRNAs play key roles in important aspects of tumorigenesis, such as cancer initiation, differentiation, growth and progression [3, 11-15], mainly by interfering with the expression of target genes involved in cell cycle, apoptosis, cell migration and invasion, angiogenesis.

This study was to determine the expression of miR-300 and association with gastric cancer formation, progression and the underlying mechanisms. We found that miR-300 was significantly reduced in human gastric cancer tissues and in gastric cancer cell lines. Using the approaches of miRNA array, systemic biology, *in vitro* manipulating expression of miR-300 and

in vivo tumor-bearing mouse model, we found that miR-300 acted as a tumor promoter in gastric cancer, which was through targeting p53.

Material and methods

Patients and samples

Based on tissue data availability, between 2010 and 2012, GC samples were included in the present study. Formalin-fixed paraffin-embedded tissues were collected from the Second and First Affiliated Hospitals of Jiangxi University of Chinese Medicine (Nanchang, China). This study was approved by the Ethics Committees of Jiangxi University of Chinese Medicine. Informed consent was obtained from all participants and the study was performed in accordance with the Declaration of Helsinki. Follow-up data were obtained from medical records and direct communication with the patients or their relatives. The follow-up period was defined as the time from the date of surgery to the date of patient mortality or the final follow-up in January 2014.

Cell culture and transfection

The human gastric cancer cell lines AGS, SGC-7901 and BGC-823 and the normal gastric epithelium cell line GES-1 were grown in RPMI 1640 medium supplemented with 10% FBS (Hyclone). The cell cultures were incubated in room air at 37°C in a humidified atmosphere of 5% CO₂.

PCR

RNA isolation and reverse transcription were performed as previously described [22]. Oligonucleotide primer sequences were as follows: β -actin (264 bp), forward: 5'-GAG ACC TTC AAC ACC CCA GCC-3'; reverse: 5'-AAT GTC AC G CAC GATT TCC C-3'; p53 (201 bp), forward: 5'-TCC CCA TCG CCA TCC CC-3' reverse: 5'-CAC CAT GGC CTC GGC TGG-3'. For all the above genes, amplification was performed under the same cycling conditions (1 minute at 94°C, 50 seconds at 57°C, 1 minute at 72°C), except the number of cycles that were specified for each gene (32 for p53).

Western blot and immunoprecipitation

AGS were harvested at specific times after treatment with regents as indicated in each ex-

periment. Cells were mixed with loading buffer and subject to electrophoresis. After electrophoresis, proteins were transferred to polyvinylidene difluoride membranes (Pall Filtron) using a semidry blotting apparatus (Pharmacia) and probed with mouse mAbs, followed by incubation with peroxidase-labeled secondary antibodies. Detection was performed by the use of a chemiluminescence system (Amersham) according to the manufacturer's instructions. Then membrane was striped with elution buffer and reprobed with antibodies against the non-phosphorylated protein as a measure of loading control. Controls for the immunoprecipitation used the same procedure, except agarose beads contained only mouse IgG.

MTT assay

Cell viability was assessed using an MTT assay. Following transfection, cells were plated in 96-well plates and incubated for 24, 48 and 72 h. A total of 20 μ l 5 mg/ml MTT (Sigma-Aldrich) was added to each corresponding test well and incubated for 4 h at 37°C. The supernatant was then discarded and 200 μ l dimethyl sulfoxide was added to each well to dissolve the formazan. Optical density was assessed by measuring the absorbance of each well at 490 nm using a spectrophotometer (SpectraMax Plus-384; Molecular Devices, Sunnyvale, CA, USA). All experiments were performed in triplicate.

Cell viability assays

An Alamar blue assay was used to measure cell proliferation. This assay is based on the quantitative metabolic conversion of blue, non-fluorescent resazurin to pink, fluorescent resorufin by living cells. After 72 h of incubation, an Alamar blue (Invitrogen) stock solution was aseptically added to the wells to equal to 10% of the total incubation volume. The resazurin reduction in the cultures was determined after a 2-6 h incubation with Alamar blue by measuring the absorbance at 530-nm and 590-nm wavelengths on a Synergy HT Multi-Mode Microplate Reader (Bio-tek Instruments).

Cell cycle analyses

DNA contents of cells were analyzed using flow cytometry as described previously. Control and transfected cells were harvested and washed twice with PBS (Phosphate Buffer Saline), fixed in 70% ethanol and kept at -20°C until analysis.

Increased miR-300 in gastric cancer




Figure 1. Up-regulation of miR-300 in gastric cancer tissues and cell lines. A. In human gastric cancer tissues compared with paired adjacent noncancerous (normal) gastric tissues, the miR-300 was up-regulated. The expression of miR-300 was analyzed by real-time PCR and normalized to RNU6B. The results are displayed on a log scale. The statistical differences between samples were analyzed with the wilcoxon signed-rank test (n=50). B. Relative expression of miR-300 in 50 gastric cancer tissues compared with matched normal tissues. Data are shown as $2^{-\Delta\Delta CT}$ values. C. The expression of miR-300 in 3 gastric cancer cell lines and one immortalized normal gastric mucosal epithelial cell line (NS: GES-1) was carried out by real-time PCR and normalized to RNU6B.

Then the cells were stained with 20 $\mu\text{g/ml}$ PI containing 20 $\mu\text{g/ml}$ RNase (DNase free) for 2 h. The stained cells were analyzed by flow cytometry (Partec Pas, Germany). The population of G0/G1, S, G2/M and sub-G1 cells was determined using Mulicycle Cell Cycle Software. The results are expressed as percentage of the cells in each phase.

In vivo tumorigenesis study

Twenty four BALB/c nude mice (female, 6-9 wk, Guangzhou Laboratory Animal Center, Chinese Academy of Sciences, Guangzhou, China) were

used in the study. Mice were maintained in a special pathogen-free (SPF) house with 12 h alternating light and dark cycles, and were given adequate nutrition and water *ad libitum*. 6×10^6 of cells suspended in FBS-free DMEM were injected into each side of the posterior flank of nude mice subcutaneously. Mice were sacrificed and tumors were collected 30 days after implantation. Tumor volume was calculated as follows: $\text{volume} = 0.5 \times \text{length} \times \text{width}^2$. Experimental protocols were reviewed and approved by the Animal Ethics Committee of Guangzhou Medical College.

Statistical analysis

Results are expressed as mean \pm standard deviation. Data were analyzed using the unpaired two-tailed student's t test and the log rank test. *P* values of $p < 0.05$ were considered significant.

Results

miR-300 is frequently up-regulated in human gastric cancer

Firstly, to determine whether the miR-300 is differentially expressed in human primary gastric cancers, the expression level of the mature miR-300 was examined using real-time PCR in 50 pairs of human gastric cancer tissues and pair-matched adjacent non-cancerous gastric tissues. Our results showed that the expression level of miR-300 was significantly increased in gastric cancer tissues in comparison with the adjacent non-cancerous gastric tissues (**Figure 1A**). About 72% of tumor samples were higher expressed with miR-300 (**Figure 1B**). Using $2^{-\Delta\Delta CT}$ values, fold change of miR-300 < 1.0 was considered as low, while it > 1.0 was regarded as high expression [18]. miR-300 expression was also evaluated in gastric cancer cell lines and one immortalized normal gastric mucosal epithelial cell line (NS). As shown in **Figure 1C**, miR-300 was significantly high expression in all cancer cell lines compared with NS. Taken together, these results provide strong evidence that miR-300 was up-regulated in gastric cancer.

Up-regulation of miR-300 increased in the proliferation of gastric cancer

AGS with a stable over-expression of miR-300 were established by transfecting miR-300 plasmids, meanwhile, the AGS/miR-NC cell line was

Increased miR-300 in gastric cancer




Figure 2. Up-regulation of miR-300 promoted growth of gastric cancers. A. The up-regulation of miR-300 promoted AGS (human gastric cancer cells) cell growth. Cell viability was measured using a WST-1 kit at indicated time points. Data are presented as mean \pm SD from three independent experiments performed in sextuple; B. miR-300 over-expression induced colony formation of AGS cells. 10^3 cells were mixed with agarose and seeded in 9-well plates for two weeks; C. The expression levels of miR-300 in the parental AGS and the AGS/miR-300 stable cell line. Data are presented as mean \pm SD. * $P < 0.05$ vs control.

established as a control. The over-expression of miR-300 in AGS/miR-300 cells was confirmed by RT-PCR (Figure 2C). Cell growth was measured using WST-1 kit at indicated time points. The results showed that up-regulation of miR-300 markedly promoted the proliferation of AGS cells (Figure 2A). The anchorage independent colony formation assay also demonstrated the same results (Figure 2B).

miR-300 promoted gastric cell migration in AGS cells.

Scratch wound-healing assay was conducted in miR-300-transfected AGS cells and control cells. Migration distance was measured at 0, 24, 48 hours after cells were scratched. The results indicated that miR-300 promoted gastric cell migration in AGS cells (Figure 3).

Correlation between p53 and miR-300 expression

Analysis of microRNA and mRNA expression data from gastric cancer tissue samples obtained from patients in Group 1 showed that p53 mRNA expression was positively correlated with miR-300 expression (Figure 4A; $r = 0.712$, $P < 0.001$). p53 expression was up-regulated in gastric cancer compared with non-cancer tissue and was higher in C1 compared with C2 patients (Figure 4B). Over-expression of miR-300 was significantly associated with shorter overall survival (OS; $P = 0.018$; Figure 4C-a). Over-expression of P53 exhibited a tendency to poor OS ($P = 0.215$; Figure 4C-b).

p53 was a direct target of miR-300 in gastric cancer cells.

To determine the mechanisms by which miR-300 promotes gastric cell proliferation, bio-informatics analysis was performed to search for miR-300 targets. CDKN1B (encoding p53), a gene critical for cell cycle [15], was predicted as a putative target of miR-300. p53 mRNA 3'UTR has a single predicted binding site that is highly conserved in mammals, and in chicken. To determine whether miR-300 could directly regulate p53, p53 mRNA 3'UTR encompassing the pre-

Increased miR-300 in gastric cancer





Figure 3. miR-300 promoted gastric cell migration in AGS cells. Scratch wound-healing assay was conducted in miR-300-transfected AGS cells and control cells. Migration distance was measured at 0, 24, 48 hours after cells were scratched. Values represent mean \pm SD. n=3. *P<0.05.



Increased miR-300 in gastric cancer

Figure 4. The correlation between miR-300 and p53 expression in gastric cancer. A. Expression of miR-300 and p53 were positively correlated ($r=0.712$; $P<0.001$). B. p53 expression level in gastric cancer vs non-cancer tissues and in the C1 vs the C2 group. Results are presented as means with 95% CI; C. Kaplan-Meier plot of overall survival according to the expression level of miR-300 and p53.




Figure 5. p53 was a direct target of miR-300 in gastric cancer cells. A. The possible miR-300 binding site in CDKN1B (p53) mRNA 3'UTR was predicted by bio-informatics analyses. The mutant seed sequence was underlined. p53 had a single predicted binding site in mRNA 3'UTR that was highly conserved in mammals, and in chicken (the complementary sequences of seed sequence of miR-300 were highlighted). B. Luciferase activities were measured in AGS cells co-transfected with the reporter constructs containing 3'UTR of p53 with or without mutant (underlined in A) and miR-300 mimic or negative-control miRNA. C. Western blot assays confirmed that p53 expression were down-regulated by miR-300 mimic in NS cells and up-regulated by miR-300 AS in AGS cells. D. p53 expression was significantly increased in p53-transfected Sw-620 cells (CMV-HA-p53) compared with that in control cells (CMV-HA). The numbers of viable AGS cells were determined by cell count 72 hours after cotransfection with miR-300 mimic and CMV-HA-p53 vector. Values represent mean \pm SD. $n=3$. $**P<0.01$.

dicted binding site with or without mutation that would disrupt miRNA interaction, were inserted to the downstream of luciferase open reading frame in pGL3-CM reporter vector. When introduced into AGS cells, the wild type p53 3'UTR reporter showed a 39% reduction in luciferase activity in the miR-300-transfected cells compared with that in scrambled-miRNA-transfected cells (Figure 5A, $p<0.01$). Mutation of miR-300 binding site abrogated the repression of luciferase activity caused by miR-300 over-expression (Figure 5A). Next, we pursued the ability of miR-300 to regulate the expression of endogenous p53. miR-300 over-expression with mimic in AGS cells dramatically repressed p53 expression (Figure 5B). Conversely, miR-300 knockdown by AS dramatically enhanced p53 expression in AGS cells (Figure 5B), indicating that endogenous miR-

300 could regulate p53 abundance. To examine the functional interrelationship between miR-300 and p53, AGS cells was simultaneously transfected with miR-300 mimic and p53-expressing vector (CMV-p53). As expected, over-expression of p53 dramatically rescued miR-300-induced growth promotion (Figure 5C and 5D, $p<0.01$), indicating that miR-300 enhanced cell proliferation possibly by repressing p53.

miR-300 targeted p53 by binding to its 3'-UTR

The p53 3'-UTR was a potential target of miR-300. miR-300 and p53 levels were analyzed by qRT-PCR and western blot, respectively. p53 levels decreased when miR-300 was up-regulated in response to the miR-300-expression vector in AGS-M cells, whereas the reverse was

Increased miR-300 in gastric cancer




Figure 6. miR-300 targeted p53 by binding to its 3'-UTR. A, B. The P53 3'-UTR was a potential target of miR-300. miR-300 and p53 levels were analyzed by qRT-PCR and western blot, respectively. P53 levels decreased when miR-300 was up-regulated in response to the miR-300-expression vector in AGS-M cells, whereas the reverse was observed for p53 expression when miR-300 was knocked down in AGS-NM cells. C. AGS-M cells were cotransfected

Increased miR-300 in gastric cancer

with miR-300 and a luciferase reporter (Luc-P53) containing a fragment of the p53 3'-UTR harboring either the miR-300 binding site or a mutant (Luc-P53-mu) in which the first six nucleotides of the miR-300 binding site were deleted. A luciferase reporter construct engineered with a non-related fragment of cDNA was used as a negative control (Luc-control). The assays showed that luciferase activity in the Luc-p53 group was significantly decreased compared to the luciferase activity of the mutant and negative control groups. D. AGS-M-miR-300 cells, which stably over-expressed miR-300, were transiently transfected with a p53 expression construct or a p53 mutant construct lacking the miR-300 binding site. AGS-M cells were transfected with p53 siRNA or a negative control siRNA. Western blot analysis for p53 showed that co-transfection of miR-300 and the p53 mutant construct produced higher levels of p53 protein than co-transfection of miR-300 and the p53 construct. p53 siRNA effectively reduced the amount p53 protein observed. E. The cell invasion assay indicated that p53 mutant constructs could reverse the effect of miR-300-mediated suppression of cell invasion. Knockdown of P53 by siRNA in AGS-M cells inhibited cell invasion. * P, 0.05.




Figure 7. Upregulation of miR-300 promoted gastric tumor growth *in vivo*. Cells stably expressing miR-300 or miR-NC were incubated in Dulbecco's modified Eagle's medium and subcutaneously injected into each side of the posterior flank of nude mice (n=24). Thirty-three days after injection, mice were sacrificed and tumors were removed. A. Tumor volume at 33 d; B. Tumor volumes were detected every three days from the time they were obvious; C. Average tumor weights. ^aP<0.05 vs control.

observed for p53 expression when miR-300 was knocked down in AGS-NM cells (**Figure 6A** and **6B**). AGS-M cells were co-transfected with miR-300 and a luciferase reporter (Luc-P53) containing a fragment of the p53 3'-UTR harboring either the miR-300 binding site or a mutant (Luc-p53-mu) in which the first six nucleotides of the miR-300 binding site were deleted. A luciferase reporter construct engineered with a non-related fragment of cDNA was used as a negative control (Luc-control). The assays showed that luciferase activity in the Luc-p53 group was significantly decreased compared to the luciferase activity of the mutant and negative control groups (**Figure 6C**). AGS-M-miR-300 cells, which stably over-expressed miR-300, were transiently transfected with a p53 expression construct or a p53 mutant construct lacking the miR-300 binding site. AGS-M cells were transfected with p53 siRNA or a negative control siRNA. Western blot analysis for P53 showed that co-transfection of miR-300 and the p53 mutant construct produced higher levels of p53 protein than co-transfection of miR-300 and the p53 construct. p53 siRNA effectively reduced the amount p53 protein observed (**Figure 6D**). The cell invasion assay indicated that p53 mutant constructs could reverse the effect of miR-300-mediated suppression of cell invasion. The results indicated that knockdown of p53 by siRNA in AGS-M cells inhibited cell invasion (**Figure 6E**).

miR-300 induced *in vivo* tumor growth

The role of miR-300 was further explored using ectopic transplantation in a nude mice model. Stable cell lines, AGS/miR-300, and AGS/miR-NC were injected into nude mice subcutaneously. Tumor growth in the miR-300 group was increased significantly when compared to the control group (**Figure 7A** and **7B**). The tumor weights of the xenograft in the miR-300 group

were lesser than those in the miR-NC group (Figure 7C). These data indicated the promoting role of miR-300 in gastric cancer.

Discussion

Recently, miRNAs have been reported to promote [16, 17] or suppress [18, 19] tumor metastasis, providing a new perspective on the metastatic process. Nonetheless, the role of miRNAs in gastric cancer (GC) metastasis is lacking. In this report, we explored and obtained for the first time metastasis-related miRNAs in GC based on a well-established metastasis cell model. The finding that miR-300 was up-regulated in metastatic GC is intriguing, as decreased miR-300 levels have been reported in several types of solid tumors [20-23], indicating that the loss of miR-300 may be a common event in tumorigenesis. In the present study, we focused on the effect of miR-300 on GC metastasis and demonstrated that miR-300 acts as a tumor promoter in GC metastasis. Restoration of miR-300 induced cell migration and invasion *in vitro* and tumor metastasis *in vivo*. To obtain stable cell lines that over-expressed miR-300, we transfected AGS-M cells with miR-300 plasmids and screened by G418. We selected twelve cell colonies in the miR-300-transfected group and found 10 out of 12 colonies exhibited remarkably uniform, stable and high-level expression of miR-300. Furthermore, three randomly chosen monoclonal cell lines exhibited similar reduction in invasive ability [24]. However, plasmid transfection strategies often result in lower integration efficiency compared to viral expression leading to the possibility of stochastic selection of rare functionally heterogeneous variants from the initial bulk population [25]. Therefore the future use of viral expression systems should create a more unbiased starting population to test our hypothesis.

Changes in miRNAs expression have been found to contribute to the initiation and progression of cancer [26]. The relationship between miRNAs and tumors has suggested that miRNAs may be altered by treatment in patients with GC [27]. In the present study, we focused on the effect of miR-300 on GC metastasis and found that miR-300 was a tumor promoter in GC metastasis. Some evidence has shown that miR-300 is associated with migration, metastasis, and drug resistance in some

tumor types [28-32], indicating that miR-300 up-regulation might contribute to these biological processes in solid tumors. In fact, we also found that miR-300 over-expression with mimic could promote gastric cell migration.

As part of our research on how the increase of miR-300 affects GC metastasis, we demonstrated that p53 was a critical downstream target of miR-300. In the present study, miR-300 and p53 were co-activated in gastric cancer samples, especially in the poor-prognosis group. miR-300 and p53 are also closely related to the development and progression of hematopoietic stem cells. This suggests that gastric cancer co-activated by miR-300 and p53 might share the same pathogenesis as leukemia. Chronic inflammation is associated with gastric carcinogenesis and there is recent evidence that *H. pylori* infection recruits bone marrow-derived cells (BMDCs) in the gastric epithelial mucosa that participate in gastric preneoplasia [33-35]. Over-expression of miR-300 and p53 may mediate the development of hematopoietic progenitor cells and gastric cancer; thus, it is necessary to elucidate the mechanism and function of the co-activation of miR-300 and p53 in gastric cancer.

The present study investigated the correlation between miR-300 and p53 expression with the malignant characteristics in patients with GC. The key finding in our study is that miR-300 promoted the proliferation of tumor cells by targeting p53 in gastric cancer. Significant correlations were observed between miR-300 and p53. Furthermore, these correlations were found to be independent of other patient characteristics. These findings indicate that high miR-300 expression may be a useful therapeutic target for GC.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Tongjun Liu, Department of Colorectal & Anal Surgery China-Japan Union Hospital of Jilin University. E-mail: liutongjun-vip5678@163.com

References

- [1] Chen J, Chen LJ, Zhou HC, Yang RB, Lu Y, Xia YL, Wu W, Hu LW. Prognostic value of matrix metalloproteinase-9 in gastric cancer: a meta-

Increased miR-300 in gastric cancer

- analysis. *Hepatogastroenterology* 2014; 61: 518-24.
- [2] Yang Y, Bai ZG, Yin J, Wu GC, Zhang ZT. Role of c-Src activity in the regulation of gastric cancer cell migration. *Oncol Rep* 2014; 32: 45-9.
- [3] Li Y, Tan BB, Zhao Q, Fan LQ, Wang D, Liu Y. ZNF139 promotes tumor metastasis by increasing migration and invasion in human gastric cancer cells. *Neoplasma* 2014; 61: 291-8.
- [4] Yu SY, Li Y, Fan LQ, Zhao Q, Tan BB, Liu Y. Impact of Annexin A3 expression in gastric cancer cells. *Neoplasma* 2014; 61: 257-64.
- [5] Oo HZ, Sentani K, Sakamoto N, Anami K, Naito Y, Uraoka N, Oshima T, Yanagihara K, Oue N, Yasui W. Overexpression of ZDHHC14 promotes migration and invasion of scirrhous type gastric cancer. *Oncol Rep* 2014; 32: 403-10.
- [6] Li XS, Xu Q, Fu XY, Luo WS. Heat shock protein 22 overexpression is associated with the progression and prognosis in gastric cancer. *J Cancer Res Clin Oncol* 2014; 140: 1305-13.
- [7] Guan SS, Chang J, Cheng CC, Luo TY, Ho AS, Wang CC, Wu CT, Liu SH. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. *Oncotarget* 2014; 5: 4868-80.
- [8] Luo BH, Xiong F, Wang JP, Li JH, Zhong M, Liu QL, Luo GQ, Yang XJ, Xiao N, Xie B, Xiao H, Liu RJ, Dong CS, Wang KS, Wen JF. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. *PLoS One* 2014; 9: e99922.
- [9] Vaiopoulos AG, Kostakis ID, Gkioka E, Athanasoula KCh, Pikoulis E, Papalambros A, Christopoulos P, Gogas H, Kouraklis G, Koutsilieris M. Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. *Anticancer Res* 2014; 34: 3083-92.
- [10] Choi MR, An CH, Chung YJ, Choi YJ, Yoo NJ, Lee SH. Mutational and expressional analysis of ERBB3 gene in common solid cancers. *APMIS* 2014; 122: 1207-12.
- [11] Musiani D, Konda JD, Pavan S, Torchiario E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. *FASEB J* 2014; 28: 4055-67.
- [12] Xu L, Qu X, Li H, Li C, Liu J, Zheng H, Liu Y. Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis in gastric cancer cells. *Oncol Rep* 2014; 32: 318-24.
- [13] Aprile G, Giampieri R, Bonotto M, Bittoni A, Ongaro E, Cardellino GG, Graziano F, Giuliani F, Fasola G, Cascinu S, Scartozzi M. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. *Expert Opin Investig Drugs* 2014; 23: 925-42.
- [14] Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, Shaker MN, Hamakawa T, Takahashi T, Takiguchi S, Mori M, Doki Y. Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer. *Ann Surg Oncol* 2014; 21 Suppl 4: S584-90.
- [15] Nielsen TO, Friis-Hansen L, Poulsen SS, Federspiel B, Sorensen BS. Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. *PLoS One* 2014; 9: e94606.
- [16] Pertino MW, Lopez C, Theoduloz C, Schmeda-Hirschmann G. 1, 2, 3-triazole-substituted olefinic Acid derivatives: synthesis and antiproliferative activity. *Molecules* 2013; 18: 7661-74.
- [17] Rasul A, Khan M, Yu B, Ali M, Bo YJ, Yang H, Ma T. Isoalantolactone, a sesquiterpene lactone, induces apoptosis in SGC-7901 cells via mitochondrial and phosphatidylinositol 3-kinase/Akt signaling pathways. *Arch Pharm Res* 2013; 36: 1262-9.
- [18] Hong KJ, Wu DC, Cheng KH, Chen LT, Hung WC. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. *J Cell Physiol* 2014; 229: 191-201.
- [19] Yang B, Jing C, Wang J, Guo X, Chen Y, Xu R, Peng L, Liu J, Li L. Identification of microRNAs associated with lymphangiogenesis in human gastric cancer. *Clin Transl Oncol* 2014; 16: 374-9.
- [20] Guo LH, Li H, Wang F, Yu J, He JS. The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer. *Int J Mol Sci* 2013; 14: 14171-84.
- [21] Liu QS, Zhang J, Liu M, Dong WG. Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer. *Cancer Sci* 2010; 101: 1807-12.
- [22] Kim YM, Kim IH, Nam TJ. Inhibition of AGS human gastric cancer cell invasion and proliferation by *Capsosiphon fulvescens* glycoprotein. *Mol Med Rep* 2013; 8: 11-6.
- [23] Tong F, Cao P, Yin Y, Xia S, Lai R, Liu S. MicroRNAs in gastric cancer: from benchtop to bedside. *Dig Dis Sci* 2014; 59: 24-30.
- [24] Fang Y, Shen H, Li H, Cao Y, Qin R, Long L, Zhu X, Xie C, Xu W. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. *Acta Biochim Biophys Sin (Shanghai)* 2013; 45: 963-72.
- [25] Wu XJ, Mi YY, Yang H, Hu AK, Li C, Li XD, Zhang QG. Association of the hsa-mir-499

Increased miR-300 in gastric cancer

- (rs3746444) polymorphisms with gastric cancer risk in the Chinese population. *Onkologie* 2013; 36: 573-6.
- [26] Shiotani A, Murao T, Kimura Y, Matsumoto H, Kamada T, Kusunoki H, Inoue K, Uedo N, Iishi H, Haruma K. Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer. *Br J Cancer* 2013; 109: 2323-30.
- [27] Yoon JH, Choi YJ, Choi WS, Nam SW, Lee JY, Park WS. Functional analysis of the NH2-terminal hydrophobic region and BRICHOS domain of GKN1. *Biochem Biophys Res Commun* 2013; 440: 689-95.
- [28] Iwaya T, Fukagawa T, Suzuki Y, Takahashi Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K, Endo F, Katagiri H, Ishida K, Kume K, Nishizuka S, Iinuma H, Wakabayashi G, Mori M, Sasako M, Mimori K. Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer. *Clin Cancer Res* 2013; 19: 6438-49.
- [29] Won KJ, Im JY, Yun CO, Chung KS, Kim YJ, Lee JS, Jung YJ, Kim BK, Song KB, Kim YH, Chun HK, Jung KE, Kim MH, Won M. Human Noxin is an anti-apoptotic protein in response to DNA damage of A549 non-small cell lung carcinoma. *Int J Cancer* 2014; 134: 2595-604.
- [30] Nakadate Y, Kodera Y, Kitamura Y, Tachibana T, Tamura T, Koizumi F. Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint. *Biochem Biophys Res Commun* 2013; 441: 793-8.
- [31] Shen J, Niu W, Zhou M, Zhang H, Ma J, Wang L, Zhang H. MicroRNA-410 Suppresses Migration and Invasion by Targeting MDM2 in Gastric Cancer. *PLoS One* 2014; 9: e104510.
- [32] McLean MH, El-Omar EM. Genetics of gastric cancer. *Nat Rev Gastroenterol Hepatol* 2014; 11: 664-74.
- [33] Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. *World J Gastroenterol* 2014; 20: 10432-10439.
- [34] Zhao H, Wang Y, Yang L, Jiang R, Li W. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. *Mol Cell Biochem* 2014; 385: 207-13.
- [35] Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y, Wu Y. miR-34a regulates cisplatin-induced gastric cancer cell death by modulating PI3K/AKT/survivin pathway. *Tumour Biol* 2014; 35: 1287-95.